



(51) International Patent Classification:

A61K 31/426 (2006.01) A61P 25/00 (2006.01)
A61K 31/277 (2006.01) A61P 37/00 (2006.01)
A61K 31/42 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/EP2018/056185

(22) International Filing Date:

13 March 2018 (13.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2017/055994

14 March 2017 (14.03.2017) EP

(71) Applicant: ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH).

(72) Inventors: CLOZEL, Martine; c/o Idorsia Pharmaceuticals Ltd Hegenheimerweg 91, 4438 Allschwil (CH).
POUZOL, Laetitia; c/o Idorsia Pharmaceuticals Ltd Hegenheimerweg 91, 4123 Allschwil (CH).


(74) Agent: GSCHWEND, Thomas; Gewerbestrasse 16, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD

Fig. 1



(57) Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*